TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sensitivity of contrast enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Longitudinal Changes in Fluid Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Longitudinal Changes in Neuroimaging Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Longitudinal changes in performance on clinical assessments
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of engagement with the Clinic To Community© (C2C) program
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Visual Analogue Scale/Score (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Endometriosis Health Profile-5 (EHP-5)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: The 5-level EQ-5D version (EQ-5D-5L)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Perioperative myocardial infarction/injury (PMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of Postpartum Family Planning Uptake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sites showing KM≥ 2 mm and AM≥ 1 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilator-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Functional MRI (fMRI) blood-oxygen-level-dependent (BOLD) responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Achieved ROSC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual asthma exacerbation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants demonstrating seroconversion from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean fold rise (GMFR) in HAI titer from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 2-year Progression-Free Survival (PFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of TEAEs meeting protocol defined DLT criteria
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline to Week 17 on the Essential Tremor Rating Scale (TETRAS) Composite Outcome Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Change From Baseline in 6-minute Walk Distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocular UCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of BSCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Grade 2 or Higher Treatment-Related Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Financial Toxicity
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change in Health related quality of life (mental health)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Health related quality of life (physical health)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Hypoglycemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to onset of symptom relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: All Cause 30 day hospital admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: All Cause 90 day hospital admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Rate of recruitment across 3 years
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of retention across 3 years
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mixed methods feedback survey at end of treatment (caregiver/patient)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Forced expiratory volume at one second (FEV1) percent predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recommended Dose of IMGN151 Monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acceptability of breath testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Force of respiratory muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Stone Free Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With SAEs and AESIs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of SAEs and AESIs
Endpoint domain: Adverse events/effects
Primary endpoint: Stoma compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of NBL-028
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall aesthetic improvement (PGAIS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall aesthetic improvement (SGAIS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC0-28days) of Buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Body Mass Index (BMI) Z-Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Childhood executive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Safety and tolerability of cAd3-Sudan Ebolavirus vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: TMP Closure Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAP Letter opened
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Patient Health Questionnaire-9
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Self-Injurious Thoughts and Behaviors Interview-Revised
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Suicide-Related Coping Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the Patient-Reported Outcome Measurement Information System (PROMIS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline in MG-ADL Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Generalized Anxiety Disorder-7 (GAD-7) scorings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Deep medullary veins score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration Of Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Classes of Guideline Directed Medical Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in preference- liking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Antigen test positive result
Endpoint domain: Adverse events/effects
Primary endpoint: Major adverse cardiac & cerebrovascular events (MACCE)
Endpoint domain: Mortality/survival
Primary endpoint: Concentration of TP-05 in whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exposure and PK of lotilaner in whole blood (AUC0-96hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exposure and PK of lotilaner in whole blood (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver SARS-CoV-2 Infection Status
Endpoint domain: Adverse events/effects
Primary endpoint: Child SARS-CoV-2 Infection Status
Endpoint domain: Adverse events/effects
Primary endpoint: Caregiver Severity of SARS-CoV-2 Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Child Severity of SARS-CoV-2 Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from implant rejection and infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Knee Injury & Osteoarthritis Outcome Score (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Vulvar burning, itching, and pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroresponse rate of varicella-zoster virus (VZV) antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Coronary Flow Reserve (CFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Residual blood volume by post bleed day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utility weighted modified Rankin Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of normal/non-obstructive CAD diagnosed through ICA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve Extrapolated From Time Zero to Infinity (AUC0-infinity) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC0-t) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppression of Serum Luteinizing Hormone (LH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Electromyography measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of patients with dacomitinib dosage change
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of patients with dacomitinib treatment discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postural stability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis Index, WOMAC
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Efficacy of Itopride Hydrochloride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placement accuracy of acetabular cup and femoral stem
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in SA victimization
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in SH victimization
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum tolerated radiation dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with fused MRI and ultrasound images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Astmakompas
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with change in systemic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiotoxic effect of chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Varicella confirmed case
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Varicella antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post ICU Syndrome-related morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in prevalence rates pre versus post index hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FACIT-F score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Length of time of Continuation of treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients completing neoadjuvant therapy and surgical resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Healthy Volunteers With Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Chronic Hepatitis B With Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of clinically significant changes in physical examination (including neurological assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monitor for the emergence of suicidal ideation and behaviour using the Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life (physical component)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete resolution of trigger finger's symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Concentration of Anti-HPV-16 IgG Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentration of Anti-HPV-18 IgG Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Zero to Last Measurable Concentration (AUC[0-t])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thigh muscle thickness by ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of hr-HPV-positive cervical smears
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality of care and guideline adoption score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction of Urgency Urinary Incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Lower Eyelid Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in extracellular volume fraction (ECV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non invasive blood pressure when sitting position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Non invasive blood pressure when standing position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in intermuscular adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Dose limiting toxicities during Cycle 1
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with Adverse Events characterized by severity, seriousness, and relationship to study drug
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with Grade 3 or Grade 4 clinical lab abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Mean cumulative protein intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of treatment-emergent Adverse events/Serious Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) and recommended Phase 2 dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Freedom from treated atrial arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reducing pain during device injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: timing of pubertal development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: HPG axis activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Labeling acquisition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Labeling retention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response rate (PR + CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients with target SUL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in peripheral blood mononuclear cell reactive oxygen species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in peripheral blood mononuclear cell NADPH oxidase enzyme activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visual Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgeon Experience
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fibrosis quantified by morphometric evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Consolidation of motor skill learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LV ejection fraction at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in LV Volume at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in global longitudinal strain at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pamira lead related SADE-d free rate
Endpoint domain: Adverse events/effects
Primary endpoint: Corticosteroid-free Endoscopic remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quality of life using KCCQ score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: rCRISS25 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short term progression
Endpoint domain: Mortality/survival
Primary endpoint: Time to secure and dress each drain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Beneficial hearing performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with sound processors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of subjects with near-complete reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Efficacy of Leuprolide Mesylate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in insulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in c-peptide concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in insulinogenic index (IGI) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Recommended RP2D of pembrolizumab, lenvatinib, N-803, and AdHER2DC vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of combination treatment in HER2 positive endometrial cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Lowering unwarranted antibiotic prescribing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Length of total hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Admission lactate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: grade 3, 4, and 5 toxicities from treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Snoring index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fluorescence imaging rate of nerve roots
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fluorescence signal ratio of nerve root to back fluorescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time taken to find the nerve root endoscopically
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline of adaptive behavior
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline in levels of blood-based biomarkers in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relationship of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects requiring hospitalization or resulting in death
Endpoint domain: Mortality/survival
Primary endpoint: Change in Number of TN Attacks per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anatomical Integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Green and Vermillion's Oral Hygiene Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibitory Control: Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibitory Control: Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endurance Performance: Time to Exhaustion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes